Keyword: Genentech

An engineered form of a naturally occurring molecule can penetrate hard-to-kill, Gram-negative bacteria.

Arvinas has filed to raise up to $100 million in its IPO to get its lead assets through the IND stage and into phase 1.

The deal features $5 billion in milestones and royalties that could land in Affimed’s bank account if the immunotherapies succeed.

The FDA cleared Roche’s cobas EGFR test for use as a companion diagnostic for AstraZeneca’s Iressa in first-line non-small cell lung cancer.

Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.

Genentech’s refillable eye implant showed positive results in a phase 2 wet AMD study, allowing patients to skip monthly Lucentis injections.

J&J executive shakeup leaves Duato with the largest portfolio; Sabry to lead partnering for Roche; Neos poaches AgeneBio chief as CEO resigns.

Roche has taken care to keep its pharma R&D group distinct from Genentech's, but is now combining partnering operations for the two.

Roche owes its pipeline to the separation of its research and early development units gRED and pRED—and it won’t be consolidating them anytime soon.

Genentech signed a $534 million contract with Microbiotica to pan gut bacteria for biomarkers, live bacterial drugs and new targets for IBD.